These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38346924)

  • 1.
    Zuur LG; de Barros HA; van Oosterom MN; Berrens AC; Donswijk ML; Hendrikx JJMA; Bekers EM; Vis AN; Wit EM; van Leeuwen FB; van der Poel HG; van Leeuwen PJ
    BJU Int; 2024 Jul; 134(1):81-88. PubMed ID: 38346924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
    Knipper S; Mehdi Irai M; Simon R; Koehler D; Rauscher I; Eiber M; van Leeuwen FWB; van Leeuwen P; de Barros H; van der Poel H; Budäus L; Steuber T; Graefen M; Tennstedt P; Heck MM; Horn T; Maurer T
    Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Maurer T; Robu S; Schottelius M; Schwamborn K; Rauscher I; van den Berg NS; van Leeuwen FWB; Haller B; Horn T; Heck MM; Gschwend JE; Schwaiger M; Wester HJ; Eiber M
    Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
    BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
    Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
    BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Armstrong WR; Kishan AU; Booker KM; Grogan TR; Elashoff D; Lam EC; Clark KJ; Steinberg ML; Fendler WP; Hope TA; Nickols NG; Czernin J; Calais J
    Eur Urol; 2024 Jul; 86(1):52-60. PubMed ID: 38290964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S; Martineau P; Plaha S; Saprunoff H; Chen C; Bishop J; Tyldesley S; Wilson D; Bénard F
    Cancer Imaging; 2024 Aug; 24(1):117. PubMed ID: 39210431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LUNAR: a randomized Phase 2 study of
    Ma TM; Czernin J; Felix C; Alano R; Wilhalme H; Valle L; Steinberg ML; Dahlbom M; Reiter RE; Rettig MB; Cao M; Calais J; Kishan AU
    BJU Int; 2023 Jul; 132(1):65-74. PubMed ID: 36797449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
    Gandaglia G; Mazzone E; Stabile A; Pellegrino A; Cucchiara V; Barletta F; Scuderi S; Robesti D; Leni R; Samanes Gajate AM; Picchio M; Gianolli L; Brembilla G; De Cobelli F; van Oosterom MN; van Leeuwen FWB; Montorsi F; Briganti A
    Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
    Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
    Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
    World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
    Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
    Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
    de Barros HA; van Oosterom MN; Donswijk ML; Hendrikx JJMA; Vis AN; Maurer T; van Leeuwen FWB; van der Poel HG; van Leeuwen PJ
    Eur Urol; 2022 Jul; 82(1):97-105. PubMed ID: 35339318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of
    Rauscher I; Düwel C; Wirtz M; Schottelius M; Wester HJ; Schwamborn K; Haller B; Schwaiger M; Gschwend JE; Eiber M; Maurer T
    BJU Int; 2017 Jul; 120(1):40-47. PubMed ID: 27862863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [
    Quarta L; Mazzone E; Cannoletta D; Stabile A; Scuderi S; Barletta F; Cucchiara V; Nocera L; Pellegrino A; Robesti D; Leni R; Zaurito P; Brembilla G; De Cobelli F; Samanes Gajate AM; Picchio M; Chiti A; Montorsi F; Briganti A; Gandaglia G
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3789-3798. PubMed ID: 38861182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.